About Savient Pharmaceuticals (OTCMKTS:SVNTQ)
Savient Pharmaceuticals, Inc. (Savient), incorporated in 1980, is a specialty biopharmaceutical company focused on commercializing KRYSTEXXA (pegloticase) in the United States and completing the development and seeking regulatory approval outside of the United States for KRYSTEXXA, particularly in the European Union. The Company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. In October 2013, the Company announced that it has elected to file voluntary petitions under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the Court). Effective January 10, 2014, Crealta Pharmaceuticals LLC, a majority owned unit of GTCR LLC acquired Savient Pharmaceuticals Inc.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Savient Pharmaceuticals (OTCMKTS:SVNTQ) Frequently Asked Questions
What is Savient Pharmaceuticals' stock symbol?
Savient Pharmaceuticals trades on the OTCMKTS under the ticker symbol "SVNTQ."
Who are some of Savient Pharmaceuticals' key competitors?
Some companies that are related to Savient Pharmaceuticals include Erickson (EACIQ), Ignite Restaurant Group (IRGTQ), Quadrant 4 Systems (QFOR), Miller Energy Resources (MILLQ), Coldwater Creek (CWTRQ), Xtera (XCOMQ), Deer Consumer Products (DEER), Cosi (COSIQ), IMRIS (IMRSQ), Baxano Surgical (BAXSQ), TranSwitch (TXCCQ), UniTek Global Services (UNTKQ), Uni-Pixel (UNXLQ), China Gerui Adv Mtals Grp (CHOPF), Corinthian Colleges (COCOQ), International Shipholding (ISHCQ), Echo Therapeutics (ECTE) and Cache (CACH).
Has Savient Pharmaceuticals been receiving favorable news coverage?
Media stories about SVNTQ stock have trended somewhat positive on Saturday, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Savient Pharmaceuticals earned a news impact score of 0.10 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 45.31 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Savient Pharmaceuticals?
Shares of SVNTQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Savient Pharmaceuticals' stock price today?
One share of SVNTQ stock can currently be purchased for approximately $0.0019.
How big of a company is Savient Pharmaceuticals?
Savient Pharmaceuticals has a market capitalization of $139,409.00.
How can I contact Savient Pharmaceuticals?
Savient Pharmaceuticals' mailing address is 1 Tower Center Blvd, EAST BRUNSWICK, NJ 08816-1145, United States. The biopharmaceutical company can be reached via phone at +1-732-4189300.
MarketBeat Community Rating for Savient Pharmaceuticals (SVNTQ)MarketBeat's community ratings are surveys of what our community members think about Savient Pharmaceuticals and other stocks. Vote "Outperform" if you believe SVNTQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SVNTQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
Savient Pharmaceuticals (OTCMKTS:SVNTQ) Analyst Ratings History
(Data available from 4/21/2016 forward)
Savient Pharmaceuticals (OTCMKTS:SVNTQ) Earnings History and Estimates Chart
Savient Pharmaceuticals (OTCMKTS SVNTQ) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/14/2013||Q3 2013||($0.28)||$6.57 million||View||N/A|
|8/14/2013||Q2 2013||($0.31)||($0.35)||$5.84 million||$6.10 million||View||N/A|
|5/15/2013||Q1 2013||($0.31)||($0.34)||$5.65 million||$4.70 million||View||N/A|
|3/19/2013||Q4 2012||($0.44)||($0.39)||$6.18 million||$4.95 million||View||N/A|
|11/8/2012||Q312||($0.45)||($0.56)||$5.87 million||$4.91 million||View||N/A|
Savient Pharmaceuticals (OTCMKTS:SVNTQ) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Savient Pharmaceuticals (OTCMKTS SVNTQ) News Headlines
No headlines for this company have been tracked by MarketBeat.com
Savient Pharmaceuticals (OTCMKTS:SVNTQ) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Savient Pharmaceuticals (OTCMKTS:SVNTQ) Income Statement, Balance Sheet and Cash Flow Statement
Savient Pharmaceuticals (OTCMKTS SVNTQ) Stock Chart for Saturday, April, 21, 2018